Biogen: raises adjusted EPS guidance for 2024
(CercleFinance.com) - Biogen reports Q3 sales of $2,466m, down 3% y-o-y.
The company reported net income, group share of $388m, a far cry from the $68m loss recorded a year earlier, giving EPS of $2.67, compared with -$0.47 in Q3 2023.
Adjusted EPS came to $4.08, down 6%.
We continue to see momentum with new product launches, and are increasingly enthusiastic about the potential of our pipeline. This quarter we have seen several significant positive developments in key areas of our late-stage pipeline, which we believe underscores the potential value for both patients and shareholders, Biogen says.
In this context, Biogen is raising its adjusted EPS guidance for 2024, now targeting $16.1 to $16.6, vs. $15.75 to $16.25 previously.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
The company reported net income, group share of $388m, a far cry from the $68m loss recorded a year earlier, giving EPS of $2.67, compared with -$0.47 in Q3 2023.
Adjusted EPS came to $4.08, down 6%.
We continue to see momentum with new product launches, and are increasingly enthusiastic about the potential of our pipeline. This quarter we have seen several significant positive developments in key areas of our late-stage pipeline, which we believe underscores the potential value for both patients and shareholders, Biogen says.
In this context, Biogen is raising its adjusted EPS guidance for 2024, now targeting $16.1 to $16.6, vs. $15.75 to $16.25 previously.
Copyright (c) 2024 CercleFinance.com. All rights reserved.